OBJECTIVE: The aims of this study were to examine: (1) the relationship between apathy and disability in late-life depression, and (2) the functional significance of improvement in apathy following escitalopram treatment in terms of its relationship to disability. METHODS:Subjects were 71 non-demented elderly with non-psychotic major depression. After a 2-week single-blind placebo period, subjects who had Hamilton Depression Rating Scale (HDRS) ≥ 18 received escitalopram 10 mg daily for 12 weeks. Apathy and disability were assessed with the Apathy Evaluation Scale (AES) and the World Health Organization Disability Assessment Scale II (WHODAS), respectively. These measures and the HDRS were administered at baseline and again following 12 weeks of treatment. RESULTS: At baseline, 38% of depressed subjects had significant apathy (AES ≥ 36.5). Severity of apathy at baseline significantly correlated with severity of disability. In a multivariate regression model, baseline severity of apathy, but not the overall depressive syndrome (HDRS), significantly correlated with baseline disability. Following escitalopram treatment, improvement in apathy significantly correlated with improvement in disability measures, while change in the rest of the depressive syndrome did not. The overall change in apathy and disability in response to escitalopram treatment was significant but small. CONCLUSION: Apathy is common in late-life depression and is associated with disability above and beyond the influence of other depressive symptoms. Given the strong relationship between apathy and disability, understanding the neurobiology of apathy and developing treatments for apathy may improve the functional outcomes of late-life depression.
RCT Entities:
OBJECTIVE: The aims of this study were to examine: (1) the relationship between apathy and disabilityin late-life depression, and (2) the functional significance of improvement in apathy following escitalopram treatment in terms of its relationship to disability. METHODS: Subjects were 71 non-demented elderly with non-psychotic major depression. After a 2-week single-blind placebo period, subjects who had Hamilton Depression Rating Scale (HDRS) ≥ 18 received escitalopram 10 mg daily for 12 weeks. Apathy and disability were assessed with the Apathy Evaluation Scale (AES) and the World Health Organization Disability Assessment Scale II (WHODAS), respectively. These measures and the HDRS were administered at baseline and again following 12 weeks of treatment. RESULTS: At baseline, 38% of depressed subjects had significant apathy (AES ≥ 36.5). Severity of apathy at baseline significantly correlated with severity of disability. In a multivariate regression model, baseline severity of apathy, but not the overall depressive syndrome (HDRS), significantly correlated with baseline disability. Following escitalopram treatment, improvement in apathy significantly correlated with improvement in disability measures, while change in the rest of the depressive syndrome did not. The overall change in apathy and disability in response to escitalopram treatment was significant but small. CONCLUSION: Apathy is common in late-life depression and is associated with disability above and beyond the influence of other depressive symptoms. Given the strong relationship between apathy and disability, understanding the neurobiology of apathy and developing treatments for apathy may improve the functional outcomes of late-life depression.
Authors: Rujvi Kamat; Erin Morgan; Thomas D Marcotte; Jayraan Badiee; Ingrid Maich; Mariana Cherner; Sergio de Almeida; Ana Paula de Pereira; Clea Elisa Ribeiro; Francisco Barbosa; J Hamp Atkinson; Ronald Ellis Journal: J Affect Disord Date: 2012-12-11 Impact factor: 4.839
Authors: M L Levy; J L Cummings; L A Fairbanks; D Masterman; B L Miller; A H Craig; J S Paulsen; I Litvan Journal: J Neuropsychiatry Clin Neurosci Date: 1998 Impact factor: 2.198
Authors: Robert S Marin; Meryl A Butters; Benoit H Mulsant; Bruce G Pollock; Charles F Reynolds Journal: J Geriatr Psychiatry Neurol Date: 2003-06 Impact factor: 2.680
Authors: Cynthia M Funes; Helen Lavretsky; Linda Ercoli; Natalie St Cyr; Prabha Siddarth Journal: Am J Geriatr Psychiatry Date: 2017-06-16 Impact factor: 4.105
Authors: Harris A Eyre; Prabha Siddarth; Kathleen van Dyk; Natalie St Cyr; Bernhard T Baune; Jorge R Barrio; Gary W Small; Helen Lavretsky Journal: Psychogeriatrics Date: 2017-01-28 Impact factor: 2.440
Authors: Patricia Marino; Herbert C Schulberg; Ariel G Gildengers; Benoit H Mulsant; Martha Sajatovic; Laszlo Gyulai; Rayan K Aljurdi; Laurie Davan Evans; Samprit Banerjee; Ruben C Gur; Robert C Young Journal: Int J Geriatr Psychiatry Date: 2017-05-22 Impact factor: 3.485
Authors: Dora Kanellopoulos; Victoria Wilkins; Jimmy Avari; Lauren Oberlin; Lindsay Arader; Merete Chaplin; Samprit Banerjee; George S Alexopoulos Journal: Am J Geriatr Psychiatry Date: 2020-01-25 Impact factor: 4.105
Authors: Matthew P White; Nicola L Yeo; Peeter Vassiljev; Rikard Lundstedt; Mattias Wallergård; Maria Albin; Mare Lõhmus Journal: Neuropsychiatr Dis Treat Date: 2018-11-08 Impact factor: 2.570